Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen's Weight Loss Result Is a Win for Eli Lilly
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight loss appears to miss the Street’s bogey of 25% weight loss and will weigh down Amgen shares,
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The drug, which is named MariTide and delivered in a monthly injection, is some time away from being sold. The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year.
15h
on MSN
These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Best Buy, Rivian, NRG Energy, Kohl’s, Semtech, and More
Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...
7d
on MSN
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund
Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2024 investor letter ...
23h
Eli Lilly Stock Is Rising Tuesday: What's Going On?
Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...
The Motley Fool on MSN
3d
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
Eli
Lilly
lost the momentum it had during the first half of the year. However, the
company
still has plenty of ...
ALS News Today
19h
Lilly to develop ALS therapies against targets ID’d with Verge tech
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
12d
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
8d
'Nuclear Option'?: Eli Lilly Taps Big Law Firms in Federal Drug Pricing Dispute
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
7d
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
7d
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...
7d
Eli Lilly and Company: Lilly announces changes on board of directors
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
Yahoo Finance
1d
Eli Lilly and Company (LLY)
Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology
company
pioneering the use of artificial intelligence (AI) and human data to transfo
Eli
Lilly
and Company
...
17h
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?
Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Amgen
General Motors
Novo Nordisk
GM
Pfizer
Feedback